211 related articles for article (PubMed ID: 31423895)
1. Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.
Han Y; Wang Z; Sun S; Zhang Z; Liu J; Jin X; Wu P; Ji T; Ding W; Wang B; Gao Q
Epigenetics; 2020; 15(1-2):122-133. PubMed ID: 31423895
[TBL] [Abstract][Full Text] [Related]
2. DHRS2 inhibits cell growth and metastasis in ovarian cancer by downregulation of CHKα to disrupt choline metabolism.
Li Z; Tan Y; Li X; Quan J; Bode AM; Cao Y; Luo X
Cell Death Dis; 2022 Oct; 13(10):845. PubMed ID: 36192391
[TBL] [Abstract][Full Text] [Related]
3. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
Kwiecińska P; Wróbel A; Taubøll E; Gregoraszczuk EŁ
Toxicol Lett; 2014 Jan; 224(2):225-32. PubMed ID: 24200999
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.
Singh BN; Zhou H; Li J; Tipton T; Wang B; Shao G; Gilbert EN; Li Q; Jiang SW
Future Oncol; 2011 Dec; 7(12):1415-28. PubMed ID: 22112317
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the dehydrogenase-reductase DHRS2 and its involvement in histone deacetylase inhibition in urological malignancies.
Müller MR; Burmeister A; Skowron MA; Stephan A; Söhngen C; Wollnitzke P; Petzsch P; Alves Avelar LA; Kurz T; Köhrer K; Levkau B; Nettersheim D
Exp Cell Res; 2024 May; 439(1):114055. PubMed ID: 38704080
[TBL] [Abstract][Full Text] [Related]
7. Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors.
Rodrigues Moita AJ; Bandolik JJ; Hansen FK; Kurz T; Hamacher A; Kassack MU
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167494
[TBL] [Abstract][Full Text] [Related]
8. DHRS2 mediates cell growth inhibition induced by Trichothecin in nasopharyngeal carcinoma.
Luo X; Li N; Zhao X; Liao C; Ye R; Cheng C; Xu Z; Quan J; Liu J; Cao Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):300. PubMed ID: 31291971
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors.
Nettersheim D; Berger D; Jostes S; Skowron M; Schorle H
J Cell Mol Med; 2019 Jan; 23(1):670-679. PubMed ID: 30460772
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
Sharma NL; Groselj B; Hamdy FC; Kiltie AE
BJU Int; 2013 Apr; 111(4):537-42. PubMed ID: 23551441
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.
Khabele D; Son DS; Parl AK; Goldberg GL; Augenlicht LH; Mariadason JM; Rice VM
Cancer Biol Ther; 2007 May; 6(5):795-801. PubMed ID: 17387270
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of histone deacetylase inhibitors and the effect on ATP-binding cassette in ovarian carcinoma cells.
Chao KC; Chang CC; Yen MS; Wang PH
Eur J Gynaecol Oncol; 2010; 31(4):402-10. PubMed ID: 20882882
[TBL] [Abstract][Full Text] [Related]
13. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
14. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells.
Wilson AJ; Holson E; Wagner F; Zhang YL; Fass DM; Haggarty SJ; Bhaskara S; Hiebert SW; Schreiber SL; Khabele D
Cancer Biol Ther; 2011 Sep; 12(6):484-93. PubMed ID: 21738006
[TBL] [Abstract][Full Text] [Related]
15. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of DHRS2 by SUV420H2 inhibits cell apoptosis in renal cell carcinoma.
Ryu TY; Lee J; Kang Y; Son MY; Kim DS; Lee YS; Kim MY; Cho HS
Biochem Biophys Res Commun; 2023 Jun; 663():41-46. PubMed ID: 37119764
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Histone Deacetylase Activity Aggravates Coxsackievirus B3-Induced Myocarditis by Promoting Viral Replication and Myocardial Apoptosis.
Zhou L; He X; Gao B; Xiong S
J Virol; 2015 Oct; 89(20):10512-23. PubMed ID: 26269170
[TBL] [Abstract][Full Text] [Related]
18. C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.
Barroilhet L; Yang J; Hasselblatt K; Paranal RM; Ng SK; Rauh-Hain JA; Welch WR; Bradner JE; Berkowitz RS; Ng SW
Oncogene; 2013 Aug; 32(33):3896-903. PubMed ID: 22945647
[TBL] [Abstract][Full Text] [Related]
19. Emerging roles of dehydrogenase/reductase member 2 (DHRS2) in the pathology of disease.
Li Z; Liu H; Bode A; Luo X
Eur J Pharmacol; 2021 May; 898():173972. PubMed ID: 33652058
[TBL] [Abstract][Full Text] [Related]
20. Combination Therapies Targeting HDAC and IKK in Solid Tumors.
Vancurova I; Uddin MM; Zou Y; Vancura A
Trends Pharmacol Sci; 2018 Mar; 39(3):295-306. PubMed ID: 29233541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
